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ABSTRACT 
The gastrointestinal tract (gut) is a complex organ whose major functions are nutrient 
and water absorption. Its functioning relies on the coordinated work of many different 
tissue types such as smooth muscles innervated by the enteric nervous system 
(ENS), which allow the motility of food intake, while the intestine’s epithelium and the 
lymphatic system (LS) play a key role in nutrient absorption. Thus gut development 
through embryogenesis requires precise fine-tuning for the establishment and 
differentiation of all its components. Interestingly, LS and ENS, two components of 
the gut that will form networks, do not develop intrinsically but rather colonize the 
immature gut from adjacent tissues. The LS develops from venous endothelial cells 
inside the cardinal vein that migrate towards VEGFC gradient coming from the 
mesenchyme. The ENS arises from two distinct populations of neural crest cells 
(NCC): vagal and sacral. The vagal cells migrate in an antero-posterior direction, 
giving rise to most of the cells composing the ENS, while the sacral cells migrate 
inversely, colonizing the post-umbilical part of the intestines. 
In this study we found that although these two systems migrate towards the gut from 
very different locations and at different stages of development, they are both 
characterized by the expression of PROX1, codifying a transcriptor factor with a 
homeodomain capable of regulating the transcription of other genes. At initial stages 
(around E5) PROX1 is expressed in the nerve of Remak (NoR), a structure formed 
from sacral NCC. Interestingly, colonization of the intestines by this population of 
cells correlates with PROX1 downregulation, around E7-8. At later stages (E14) 
PROX1 expression is turned on again between the circular and longitudinal muscles, 
this time labeling the LS. Once specified the LS, PROX1 expression is always 
maintained. Between E15 and E18, the LS develops towards the epithelium. 
Further studies with in ovo and in vitro electroporation technique will be done in order 
to misexpress PROX1 in the NoR and address its function during ENS development. 
 
 
 
 
 
 
 
 
Key words: gastrointestinal tract; lymphangiogenesis; PROX1; enteric nervous 
system; sacral neural crest cells.
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RESUMO 
O sistema gastrointestinal é um órgão vital, complexo e conservado entre os 
vertebrados. O seu desenvolvimento embrionário inicia-se no estádio HH8 com o 
aparecimento de uma invaginação na zona anterior do embrião. Em HH13, a 
segunda invaginação dá-se na zona posterior e estas duas alongam-se até à zona 
do embrião que se encontra ao nível do saco vitelino. Este tubo primitivo 
endodérmico é entretanto rodeado por mesoderme e estas duas camadas vão-se 
desenvolvendo, regionalizando-se em tubo digestivo anterior, médio e posterior. 
Após todos os processos de diferenciação estarem concluídos, o sistema 
gastrointestinal divide-se em faringe, esófago e estômago (tubo digestivo anterior), 
intestino delgado (tubo digestivo médio) e intestino grosso (tubo digestivo posterior). 
No modelo ave, algumas diferenças existem anatomicamente relativamente ao 
modelo mamífero: o papo substitui o esófago e as duas partes que constituem o 
estômago: fundus e antrum correspondem ao proventriculus e moela. O fundus é 
conhecido como a parte glandular do estômago e o antrum como a parte muscular. 
Em termos de citodiferenciação, o intestino é composto pela mucosa, submucosa, 
camadas musculares e serosa. Entre o músculo circular liso e longitudinal situa-se o 
plexus Auerbach ou mientérico; um segundo plexus existe também na camada 
submucosa, denominado de Meissner. 
Ao longo do sistema gastrointestinal, três grandes vasculaturas desenvolvem-se: 
sistema cardiovascular, linfático e entérico nervoso. Estas em conjunto com as 
células do músculo liso permitem que o sistema gastrointestinal cumpra as suas 
funções de digestão dos alimentos com a respectiva absorpção de nutrientes e 
água. 
O sistema linfático composto por veias, nódulos linfáticos e órgãos linfóides, tem 
funções ao nível da absorção, mas também na proteção contra agentes invasores e 
regulação da homeostasia. Embora seja um sistema de alta importância para o trato 
digestivo, este ainda se encontra por estudar, sendo apenas compreendido ao nível 
do seu primeiro surgimento na veia cardinal (E9 no modelo ratinho). A sua 
proximidade com o sistema cardiovascular advém de algumas células localizadas 
dorso-lateralmente na veia cardinal começarem a expressar Sox18 que, por sua vez, 
activa Prox1. Uma vez expresso o factor de transcrição Prox1, estas células já estão 
especificadas como endoteliais linfáticas, sendo sempre necessária a sua expressão 
para que a sua identidade se mantenha. Ao longo do eixo antero-posterior da veia, 
os conjuntos de células que expressam Prox1 vão aumentando o número de células 
a expressarem este gene e iniciam a sua migração em relação a um gradiente 
químico de VEGFC. O gradiente VEGFC é expresso pela mesoderme lateral e a 
indução da migração acontece por via de activação e dimerização dos receptores 
VEGFR3. Embora este receptor seja comum ao sistema circulatório cardiovascular, 
aquando do momento de migração das células endoteliais linfáticas este receptor 
não é expresso pelas células endoteliais sanguíneas. Essa migração leva à 
constituição de sacos linfáticos, que se expandem e fundem com outros sacos 
linfáticos, formando toda a rede linfática do corpo. A separação entre sistema 
cardiovascular e linfático acontece por via da expressão do gene Podoplanina, 
codificando uma proteína transmembranar do tipo das mucinas, que promove a 
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agregação de plaquetas sanguíneas na zona de comunicação entre os dois 
sistemas. Este mecanismo é conhecido como o mecanismo de desenvolvimento 
geral do sistema linfático e embora seja responsável pela formação de toda a 
vasculatura linfática, o modo como ele atinge e se desenvolve nos órgãos está ainda 
por se determinar.  
Um outro sistema também importante para a fisiologia do sistema digestivo é o 
sistema entérico nervoso. Este sistema é responsável pelo movimento das células 
musculares lisas, facilitando os movimentos gastrointestinais e fluxo sanguíneo. O 
seu desenvolvimento dá-se a partir de células da crista neural de duas origens 
diferentes: vagal e sacral. Estas células encontram-se respectivamente no tubo 
neural entre os sómitos 1 e 7, e a partir do sómito 28º. Entre o limite do tubo neural e 
da ectoderme não neural, encontram-se estas células vagais e sacrais que sofrem 
uma transição epitélio-mesênquima, delaminam do epitélio e migram para o sistema 
gastrointestinal. 
Em galinha, as células sacrais formam uma estrutura externa ao cólon, mas próxima 
deste, denominada nervo de Remak. A sua extensão é desde o cólon até à parte 
pós-umbilical e ao contrário das células vagais, elas migram primeiro em direção ao 
plexus mientérico e somente depois para a submucosa. Esta migração do nervo 
para o cólon ocorre aproximadamente a E7.5, seguindo-se depois na direcção 
caudo-rostralmente. O sistema entérico nervoso é maioritariamente derivado das 
células vagais, mas as sacrais ainda contribuem 17% para a inervação do cólon. 
Diferentes vias de sinalização regulam a migração destas células no eixo antero-
posterior, sendo as duas mais importantes as vias RET/GFRα1/GDNF e 
EDNRB/EDN3. 
Na via RET/GFRα1/GDNF, o ligando GDNF é expresso no mesênquima do 
estômago e cecum em diferentes estádios temporais, mas sempre numa posição 
anterior à frente das células vagais em migração. Este ligando promove a 
sobrevivência e proliferação dos precursores do sistema entérico nervoso e pensa-
se que seja a principal via que regula a migração das células vagais, uma vez que 
estas expressam o receptor GFRα1. Contudo, na zona do cólon não existe nenhum 
ponto em que haja expressão significativa de GDNF, o que pode significar que outro 
mecanismo actue na regulação da migração dos precursores do sistema entérico 
nervoso nesta zona do sistema digestivo. 
A via EDNRB/EDN3 influencia a migração das células precursoras do sistema 
entérico nervoso. Em ratinho, o ligando Edn3 é expresso inicialmente nas células 
mesenquimatosas do tubo digestivo anterior e médio, mas mais tarde restringe-se 
ao cecum e cólon proximal. O receptor EdnrB é, por sua vez, fortemente expresso 
pelas células da crista neural em migração. Antagonistas deste receptor levam a 
problemas na migração destas células. 
Apesar do sistema linfático e entérico nervoso migrarem de regiões diferentes e em 
estádios embrionários distintos, neste projecto mostrou-se que são regulados pelo 
mesmo factor de transcrição PROX1.  Em estádios precoces (E5), PROX1 é co-
expresso com SOX10 no nervo de Remak. Por volta de E7.5-E8, a expressão de 
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PROX1 diminui e desaparece, mantendo-se a expressão de SOX10 nas células 
sacrais da crista neural. Esta diminuição é observada tanto ao nível do mRNA como 
da proteína, sendo que nos estudos de imunohistoquímica o desaparecimento da 
expressão de PROX1 coincide com a entrada das células sacrais no cólon. Uma vez 
que PROX1 é expresso unicamente pelas células sacrais e não vagais, PROX1 
torna-se no primeiro marcador encontrado que é diferencialmente expresso pelas 
duas populações de células do sistema entérico nervoso. Diferentes técnicas foram 
realizadas: ablação mecânica e química, in vivo e in vitro das células sacrais, e 
todas comprovaram a expressão de PROX1 por estas células. 
Mais tarde (E14), PROX1 surge entre as camadas de músculo liso circular e 
longitudinal do cólon, desta vez especificando o sistema linfático. Entre E15 e E18, 
as células endoteliais linfáticas migram das camadas musculares até à submucosa. 
Os resultados deste projecto mostram uma regulação temporal de PROX1 no 
desenvolvimento dos sistemas entérico nervoso e linfático. Tendo em conta a 
observação de uma expressão diferencial pelas células da crista neural sacral e 
vagal, os próximos estudos focar-se-ão na função da expressão de PROX1 pelas 
células sacrais. Os estudos de desregulação génica de PROX1 irão recorrer às 
ténicas de microinjecção e electroporação e terão como objectivo testar se PROX1 
inibe a entrada das células sacrais no cólon. 
 
 
 
 
 
 
 
 
 
 
 
 
Palavras-chave: trato gastrointestinal; linfangiogénese; PROX1; sistema entérico 
nervoso; células sacrais da crista neural 
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Chapter I 
 
 
INTRODUCTION 
 
I.1. The gastrointestinal tract 
 
The gastrointestinal tract, also called gut, is a complex, specialized and vital organ 
system responsible for the digestion of food, absorption of nutrients and water, and 
waste disposal. Its complexity and specialization is achieved during embryonic 
development through very finely tuned gene regulation processes along the antero-
posterior axis, and from contributions of the three germ layers. The endoderm gives 
rise to the epithelium, the splanchnic mesoderm forms the visceral smooth muscle 
and ectoderm innervates the gut through neural crest derived cells. Mechanisms of 
gut development are highly conserved through evolution, and are thus very similar 
not only in birds and mammals, but among vertebrates in general 1. 
 
I.1.1. Gut morphogenesis, patterning and function 
 
Early development of the digestive tract directly follows gastrulation and starts with a 
sequence of two endodermal invaginations. The first fold, named anterior intestinal 
portal (AIP), occurs at an anterior position of the embryo, and is quickly followed by a 
second fold named caudal intestinal portal (CIP), at the posterior extremity. In the 
chick model these events take place around HH8 2 for the AIP, and HH13 for the 
CIP. These two invaginations elongate and fuse in the middle of the embryo at the 
level of the yolk stalk around HH24. In the meantime, the splanchnic mesoderm 
surrounds this primitive endodermal tube, and interactions between these two tissues 
specify the mesoderm into the digestive mesenchyme 3. Later on, after the primitive 
gut has formed, two independent populations of NCC (vagal and sacral) colonize it to 
form the ENS 4 (Figure 1). 
Despite differences in size and shape, organs that compose the gut are similar 
among vertebrates. A standard gut is initially composed of three parts: foregut, 
midgut and hindgut, that will later differentiate into pharynx, esophagus and stomach 
(foregut), small intestine (midgut) and large intestine (hindgut). In most vertebrates, 
the stomach is divided in two parts: fundus and antrum. The fundus (or glandular 
stomach) forms the anterior part and it is composed of gastric glands that secret 
pepsinogen and hydrochloric acid, responsible for hydrolyzing proteins. The antrum 
(or muscular stomach) forms the posterior part; it has a function of breaking food into 
smaller pieces. It also possesses specialized glands that secrete protective mucus 
into the lumen. At the junction of the stomach and the small intestine resides the 
pyloric sphincter, which controls the food's passage from the stomach to the intestine 
and prevents reflux from the intestine into the stomach 1.  
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Figure 1 - Gut morphogenesis. 
(A) Surface view of an embryo HH7. (A1) Formation of head fold and foregut at HH7 viewed 
in a sagittal section. (B) Surface view of an embryo HH8. (B1) Sagittal section at HH8, 
showing a deeper head fold with an increase in foregut length, the anterior intestinal portal. 
(C-F) Sagittal sections of embryos: HH12-13 (C), HH13-14 (D), HH18 (E), HH20 (F) with the 
initial formation of posterior intestinal portal that develops into hindgut and later cloaca 
formation. Images were adapted from 3. 
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The small intestine is composed of three parts: duodenum, jejunum and ileum, 
whose distinction is made based on the different cell types composing their epithelial 
layer 5. 
The duodenum is responsible for mixing the food with bile from the gallbladder and 
pancreatic secretion from pancreas. Bile breaks down fat particles into smaller 
droplets and pancreatic secretions converts fats into fatty acids and glycerol. 
Chemical food breakdown is completed in jejunum thanks to a combination of 
pancreatic enzymes with enzymes produced by the jejunum epithelial wall. The last 
part of the small intestine (ileum) is responsible for nutrient absorption. Finally, the 
large intestine is composed of: colon, rectum and anus. Its function is mainly water 
absorption from the food before the excretion of unused material (feces) out of the 
body. 
Few differences between the standard gut and the gut in the avian model are 
noticeable: the crop substitutes the esophagus; the two parts that compose the 
stomach are physically separated into proventriculus (fundus) and gizzard (antrum); 
cecum is the equivalent of appendix in mammals 1 (Figure 2). The main difference is 
localized in the posterior part, where the cloaca, that corresponds to a common 
digestive and urinary chamber that is transient in all other vertebrates, is maintained 
only in birds 1,6. 
 
 
 
 
Figure 2 - Gut differentiation along the 
antero-posterior axis. 
Initially the gut is divided into 3 parts: foregut, 
midgut and hindgut. Later, there is a 
differentiation of the foregut into proventriculus, 
pyloric sphincter and gizzard; midgut into small 
intestine and hindgut into cecum, large intestine 
(colon) and cloaca. Image adapted from 7. 
 
 
 
I.1.2. Gut layer composition and tissue interaction 
 
Despite morphological differences in the organs composing the gut, the radial 
distribution of tissue layers is similar all along the antero-posterior axis. Four layers 
can be distinguished: mucosa, submucosa, muscular layer and serosa. 
The mucosa is a lamina propria made of connective tissue rich in blood and 
lymphatic vessels associated with smooth muscle cells. Sometimes the mucosa layer 
contains glands, lymphoid tissue and a muscular mucosa layer, which is composed 
of two thin sub-layers of smooth muscle cells separating the mucosa from the 
submucosa layer. The submucosa is the adjacent layer made of connective tissue, 
blood and lymphatic vessels, and the Meissner plexus of the ENS. The muscular 
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layer is made of smooth muscle cells divided in two sub-layers: circular and 
longitudinal. The circular muscle layer is localized closer to the submucosa; between 
the two muscles we find the second ENS plexus: the Auerbach's plexus in where 
blood and lymphatic vessels are also present. Finally, the serous layer (the most 
external) is a thin layer of connective tissue with blood and lymphatic vessels and a 
fat tissue that covers a simple squamous epithelium (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 - Gut composition through the radial axis. 
From the inner to the outer part of the gut four layers constitute this organ: submucosa, 
mucosa, muscularis and serosa. Besides the smooth muscle layers it is also visible the LS 
(green), blood vessels (blue and red) and the ENS (yellow). Image from 8. 
 
 
Throughout the whole gut, three major networks develop: the blood vascular system, 
the LS and the ENS. These structures are essential for a proper development of the 
gut, and they will later play key roles in the functional activity of the gut. The 
presence of LS within the mucosa and submucosa in association with epithelium 
protects the organism against bacterial invasion, since it distributes macrophages 
and lymphoid cells in these regions. Through ENS activity, the muscular mucosa 
promotes movements of the mucosa, important for contacts between food and 
mucosa. This facilitates access to food and increases the absorption of nutrients by 
blood vessels and fat by lymphatic network 9. 
 
I.2. Lymphatic system network 
 
The LS is a vascular network widely spread through the body and intermingled to the 
blood vasculature. However, despite this overall overlap, these two networks are only 
connected together at the level of the left sub-clavian vein. The LS is made of 
vessels, lymph nodes and lymphoid organs 10. One of the main roles of this network 
is related to body homeostasis by regulating the volume of interstitial fluid retained in 
organs. Other essential functions of the LS are: collection of wastes and proteins 
excess towards the circulatory system, and immune surveillance 11,12. During 
lymphangiogenesis, mutation in key regulatory genes lead to major developmental 
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defects, such as inherited lymphedemas (swelling causing pain due to lymph 
accumulation in tissues). Finally, a local reactivation of lymphatic development is 
sometimes observed in and around cancer tumors leading to metastatic propagation 
of malignant cells to the entire body. 
The close proximity to the cardiovascular system arises from its own developmental 
events. Lymphatic endothelial cells (LEC), the cells that compose the LS are first 
specified from a subpopulation of blood endothelial cells (BEC) localized dorso-
laterally in the paired cardinal veins. LEC specification starts in these cells with the 
expression of Sox18 (E9 in the mouse), which in turn activates Prox1, the key 
regulator of lymphangiogenesis 13-15. At any point in development, a loss of Prox1 
expression causes these cells to lose their lymphatic identity returning to a blood 
endothelial cell fate and causing aberrant junctions of lymphatic vessels with blood 
vessels 16. As soon as they are specified, LEC form clusters of Prox1 cells along the 
antero-posterior axis of the vein. These clusters augment their number of Prox1 cells 
and migrate through VEGFR3/VEGFC signaling, forming small sacs that will later 
expand and fuse together, to constitute lymph sacs 17. The protein Podoplanin 
(PDPN) a mucin-type transmembrane glycoprotein is responsible for platelet 
aggregation, cutting connections between the cardinal vein and lymph sacs which 
results in the separation between blood and lymphatic vessels 18 (Figure 4). It is still 
not clear whether the whole lymphatic vasculature is derived from these lymph sacs 
or if other processes are involved. 
 
 
 
 
 
 
 
Figure 4 - Events of lymphatic system 
development. 
(A-C) After artero-venous specification, 
some cells present in the dorso-lateral part 
of the cardinal vein start expressing LYVE-1 
and SOX18. At this developmental time both 
blood vessels and LEC express VegfR3. 
While Prox1 is expressed, VegfR3 is 
downregulated in BEC and maintained 
strongly expressed in LEC, which permits 
their migration towards the increasing VegfC 
gradient (D). As migration proceeds lymph 
sacs form and progressively isolate from the 
cardinal vein due to platelet aggregation 
caused by PDPN (E). All the lymphatic 
vasculature is established from lymph sacs 
proliferation and fusion to each other (F). 
Image adapted from 13. 
 
PDPN 
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VEGFR3/VEGFC signaling can both activate BEC and LEC but when lymphatic 
vessels start sprouting from the cardinal vein, VEGFR3 is downregulated in BEC. 
VEGFC binds to VEGFR3 provoking a dimerization with another VEGFR3, which 
activates two signaling pathways: PI3K-Akt and ERK. As seen in Figure 5 a 
downregulation of ERK by Akt activity can serve as a critical control in LEC sprouting 
and also contribute to LEC differentiation and maintenance of lymphatic activity 19. 
These mechanisms describe how specification, determination and expansion of the 
LS occur. However, how this system migrates into specific organs, such as the gut 
still needs to be determined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 5 - Signaling pathways involved in lymphangiogenesis. 
VEGFC binding to VEGFR3 induces its dimerization, which provokes the activation of two 
signaling pathways: PI3K-Akt and ERK. Akt downregulates ERK functioning as a control to 
maintain LEC sprouting and its differentiation. BMP2 signaling pathway also affects 
lymphangiogenesis, inhibiting LEC fate. Image from 19. 
 
 
I.3. Enteric nervous system network 
 
The ENS, also called “second brain", is formed by neurons and glia that innervate the 
entire gut. This system coordinates gut motility and blood flow, and modulates 
endocrine and immune functions, all commanded partly by the central nervous 
system 20. 
The ENS is organized into two plexi: Meissner and Auerbach which display different 
localizations. Meissner's plexus is present within the submucosa layer while 
Auerbach's is situated between the circular and longitudinal muscle layers.  
The ENS arises from NCC, cells present at the boundary of the neural plate and non-
neural ectoderm that undergo an epithelium-mesenchymal transition (EMT) and 
delaminate from the epithelium, migrating through specific pathways 21. NCC are 
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multipotent stem cells that will give rise to different cell types such as melanocytes, 
bone and cartilage of the face, or enteric neurons and glia depending on their 
localization along the neural tube. 
Two types of NCC form the ENS of the gut, the vagal NCC and the sacral NCC. 
Vagal NCC migrate ventrally from the neural tube located at the level of somites 1-7 
at embryonic day 3 (E3). They first accumulate in caudal branchial arches before 
entering by the foregut mesenchyme. Inside the gut their migration goes rostro-
caudally reaching the posterior end around E8-E8.5 in chicken embryos 4,22. 
Interestingly, their migration behavior within gut mesenchyme changes along the 
antero-posterior axis. In the pre-umbilical 
gut, vagal NCC are evenly distributed 
within the mesenchyme, while in the post-
umbilical gut they migrate in the outermost 
layer of the mesenchyme. Finally, when 
they reach the hindgut, they colonize first 
the inner submucosa layer. The exact 
reasons for this behavior are not clear but 
it seems that this is linked to mesenchyme 
differentiation into muscles 23. 
Sacral NCC are present on the neural 
tube from somite 28th and caudalwards; at 
E4 they migrate ventrally to form a 
structure specific to birds called the Nerve 
of Remak (NoR). This nerve develops 
exterior to the gut but in close proximity to 
it. It extends from the posterior end of the 
hindgut to the anterior limit of the post-
umbilical gut. At E7.5 these cells migrate 
out of the NoR entering the hindgut. They 
first form a part of the myenteric plexus 
before spreading to the submucosa 
plexus. In contrast to vagal cells, sacral NCC migrate in a caudo-rostral manner. 
These cells only colonize the post-umbilical gut, contributing in 17% of hindgut's 
ENS. Thus vagal NCC give rise to the greatest part of ENS 22 (Figure 6). 
These mechanisms of EMT, migration, and differentiation undergone by NCC require 
very precise gene regulation, and cell-cell interactions 25. A failure in any of these 
steps will severely impact ENS formation and will lead to one of the many 
pathologies associated to ENS development defects. The most known congenital 
obstructive disorder is the Hirschsprung's (HSCR) disease, characterized by an 
incomplete formation of ENS (agangliogenesis) in the distal intestine. Unfortunately, 
mechanisms leading to this pathology are poorly understood, and there is a need to 
better understand its development, and the contribution of these two populations of 
NCC to the innervation of the distal gut. To date, no marker allowing to distinguish 
vagal from sacral NCC, has been found.  
Figure 6 - Enteric nervous system 
ontogeny. 
Vagal NCC arise from neural tube close 
to somites 1-7 and sacral NCC from 
somite 28th caudalwards. Vagal NCC 
colonize the entire gut and sacral NCC 
only migrate until the post-umbilical gut. 
Image adapted from 24. 
E8-E8.5 
> E3 
E4 
ßE7.5 
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I.3.1. Signaling pathways involved in antero-posterior migration of 
neural crest cells 
 
The HSCR disease is the most common and most studied congenital ENS 
pathology. Patient analyzes have identified two relevant pathways: 
RET/GFRα1/GDNF and EDNRB/EDN3 with major importance in signaling through 
the RET receptor, as heterozygous mutation in RET are found in 50% of familial and 
sporadic cases. On the other hand, GDNF and GFRα1, have either rarely been found 
or never been described in HSCR cases. Regarding the second implicated pathway. 
Mutations in the second pathway, EDNRB and EDN3, are found in 5% of HSCR 
cases 26.  
Starting with RET/GFRα1/GDNF signaling, RET is a receptor tyrosine kinase with 
two isoforms: RET9 and RET51 that bind to Glial-cell-line-derived neurotrophic factor 
(GDNF) through GPI-linked co-receptor GFRα1. While mice expressing only the 
RET9 isoform are phenotypically normal, those only expressing RET51 lack enteric 
ganglia, similar to HSCR disease 27,28. In vitro studies have shown that RET ligand, 
GDNF is a chemoattractant that promotes survival and proliferation of ENS 
precursors cells that later differentiate into enteric ganglia 29-32. In mice, Gdnf 
expression occurs within gut mesenchyme in two regions (called hot spots): stomach 
and cecum mesenchyme 33,34. The appearance of these two hot spots is temporary 
separated and always occurs spatially ahead of the vagal NCC wavefront. This 
together with the fact that GDNF is a chemoattractant and that vagal NCC express 
Gfrα1, indicate that these hot spots attract vagal NCC, inducing a colonization 
movement throughout the gut. However this mechanism is not applicable to the 
hindgut, since no hot spot has been found caudal to the cecum 8 (Figure 7). 
Interestingly, an in vitro study using HEK-293T cells misexpressing RET 36 showed 
that in the absence of RET ligand GDNF, cells suffer apoptosis. They found that this 
receptor is a dependent receptor: in the presence of its ligand (GDNF), positive 
signals are sent to induce ENS proliferation; while the absence of GDNF binding, 
provides negative signals that initiate a pro-apoptotic program. This finding brought 
new insights into the understanding of HSCR disease, since this disease could be 
caused by specific mutations in RET that lead to problems in sensing GDNF gradient 
or by the absence of a chemoattractant gradient of GDNF without mutations in RET. 
The second identified pathway: EDNRB/EDN3 pathway regulates NCC migration 
inside the gut. Endothelin-3 (EDN3) is a ligand in a family of secreted peptides and 
binds to 7-transmembrane G-protein coupled receptor, Endothelin receptor-B 
(EDNRB). 
In mice, EdnrB is expressed in gut mesenchyme as well as in migrating NCC where 
its expression is stronger. As for Edn3, it is widely expressed in foregut and midgut 
mesenchymal cells but is later restricted to cecum and proximal colon 37,38. Several 
studies have shown the importance of this pathway in NCC migration inside the gut 
mesenchyme. In mice, a loss of function mutation for one of these genes cause 
agangliogenesis in the distal gut 8, and antagonists of EDNRB where shown to affect 
NCC migration, also causing distal agangliogenesis 39 (Figure 7). 
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Other roles for this pathway where shown in various studies such as: decreased 
number of neural crest stem cells in guts of Edn3-/- mice compared to wild-type 37; or 
inhibition of neurogenic and gliogenic lineage commitment in EDN3-treated NCC with 
a mimicked effect seen in Sox10 overexpression 40. Altogether, these results indicate 
a role in controlling neural crest stem cells and an interplay between EdnrB and 
Sox10 signaling pathways 41,42. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 - Phenotypes of mice with mutations in RET/GFRα1/GDNF and EDNRB/EDN3 
signaling pathways. 
Grey dots represent NCC colonization throughout the gut. HS= hot spot. 
Figure adapted from 35. 
 
  
 
I.4. Objectives 
 
Most developmental studies on LS development have addressed the initial formation 
and migration of LS precursors from the cardinal vein. In contrast, LS arrival to 
organs, in particular the gut, still needs to be elucidated. In order to fill this gap, our 
first goal was to describe the temporal and spatial arrival of the LS into the colon. 
In the second part of our study, we focused on PROX1 expression in sacral NCC, 
and investigated its function in the potential regulation of their entrance into the 
hindgut. 
RET/GFRα1/GDNF 
+/+ 
Ret 9/9 
Ret 51/51 
Ret - / - 
Gfrα1 - / - 
Gdnf - / - 
EDNRB/EDN3 
+/+ 
EdnrB - / - 
Edn3 - / - 
HS HS 
HS 
HS 
HS 
HS 
HS 
HS HS 
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Chapter II 
 
 
MATERIALS AND METHODS 
 
II.1. Embryo collection 
Fertilized White Leghorn chicken eggs (Gallus gallus) were obtained from Haas Farm 
in France and incubated in a humidified atmosphere at 38ºC. Embryos were 
collected at the desire embryonic day of gestation (E) and their stage confirmed with 
Hamburger and Hamilton staging 2. 
 
II.2 In situ hybridization (ISH) probe production 
II.2.1. Total RNA isolation and cDNA production 
Total RNA was isolated from an E6 whole embryo using the RNeasy Midi Kit 
(Qiagen). The RNA extract was diluted in RNase free water (Sigma-Aldrich); 
concentration and purity were measured with a spectrophotometer. RNA was stored 
at -80ºC until needed for cDNA production. The cDNA production protocol is 
described in Annex A1 (RT-PCR). cDNA was stored at -20ºC. 
Primer design for the RNA probes LYVE1, PODOPLANIN, PROX1 and SOX10 is 
detailed in Annex A2. CLAUDIN5 probe was kindly given by Dr. Aimee Ryan. 
The PCR reaction protocol and PCR product ligation into plasmids, bacteria 
transformation and plasmid amplification and extraction are all described in Annex 
A3-A5. 
 
II.2.2. Plasmid linearization and purification 
For plasmid linearization, 10 µg of plasmid was digested with 10 U of a restriction 
enzyme during 2 hours at 37ºC (Annex B, Table B4). The efficiency of digestion was 
visualized on a 2% agarose gel. Purification of the digested DNA was performed 
using the kit Nucleospin Gel and PCR clean-up (Macherey-Nagel). 
 
II.2.3. Probe transcription and purification 
1 µg of the linearized plasmid (in a maximum volume of 5 µL) was incubated at 37ºC 
during 2 hours with 2 µL of transcription buffer 10X (Roche), 1.2 µL of DIG nucleotide 
mix (Roche), 1.2 µL of DTT (Invitrogen), 1.2 µL of RNASE out (Invitrogen), 2 µL of 
RNA polymerase (Annex B, Table B4) and RNase free water up to a final volume of 
20 µL. After the digestion reaction, 2 µL of DNASE (Roche) was added to the
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reaction for 10 minutes at 37ºC, and stopped on ice. Probe size was monitored on a 
2% agarose gel. 
Probe purification was performed using MicroSpinTM G-50 Columns kit (GE 
Healthcare), eluted in a final volume of 30 µL. Its concentration was measured with a 
spectrophotometer and stored at -20ºC. 
 
II.3. In situ hybridization 
Guts dissected from E6 to E16 chick embryos were fixed with 4% paraformaldehyde 
(Electron Microscopy Sciences) in PBS (4% PFA), fixation time depending on 
sample's size/developmental stage (Annex B, Table B5). A quick wash was done 
with PBS 1X (BioWhittaker) followed by a second wash equal in time to the fixation 
time. From this step on, all the timings were equal to those used for fixation. Then, 
dehydration was performed with increasing concentrations of methanol diluted in 1X 
PBS (PBS). Guts were stored in 100% methanol at -20ºC until use. 
Day 1 
Guts were rehydrated with decreasing concentrations of methanol-PBS for 10 
minutes each (or 20 minutes in case of guts from older embryos). Two washes with 
PBS were done and samples were left for exactly 1 hour in a solution of 6% H2O2 
(Sigma-Aldrich)-PBS to diminish their endogenous alkaline phosphatase activity. 
Subsequently, they were washed 3 times in PBT (0,1% Tween-20 in PBS) and 
incubated with Proteinase K (VMR) in a dilution of 1:1000 (incubation time was 
adjusted according to embryo stage - Annex B, Table B6). A 10 minutes wash was 
done with PBT-glycine in a concentration of 2 mg/mL, followed by 2 washes of PBT 
and a 20 minutes post-fixation in 0,2% glutaraldehyde-4% PFA. Samples were then 
washed 2 times in PBT and placed 1 hour at 70ºC in warmed hybridization 
solution. Finally, samples incubation with probes was done at 65ºC overnight at a 
concentration of 70 ng/mL. 
Day 2 
Embryos were washed 3 times, 30 minutes each, with a pre-warmed solution 1 at 
70ºC, followed by 3 washes, 30 minutes each, in solution 2 at 65ºC. Next, 3 washes 
of 5 minutes were done with Tris-Buffered Saline (TBS) 0,1% Tween-Levamisole 
(TBST-Levamisole) (1:100) followed by a blocking of 2,5 hours in 10% fetal bovine 
serum (Sigma-Aldrich) in TBST-Levamisole done at room temperature with agitation. 
During this time, antibody blocking was also prepared by adding a small amount of 
embryo powder (Annex A6) to 1mL of TBST-Levamisole and incubated for 30 
minutes at 70ºC. A quick vortexing was performed and the solution was cooled on 
ice. The anti-Digoxygenin antibody coupled with alkaline phosphatase (Roche) was 
added to this solution and centrifuged for 10 minutes at 1000 rpm and 4ºC. The 
supernatant was collected and mixed in a TBST-Levamisole-1% fetal bovine serum 
solution, added to each vial, and incubated overnight at 4ºC rocking. The final 
concentration of the antibody was 1:2500. 
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Day 3 
3 washes of 5 minutes were done with TBST-Levamisole, followed by 5 washes of 
TBST-Levamisole each during 1 hour with agitation. The final wash was left with 
agitation overnight at 4ºC. 
Day 4 
2 washes, 10 minutes each, were performed with Trizma hydrochloride solution 0,1M 
pH=8 (Sigma-Aldrich)-LT (1:100) diluted in DEPC-treated water. Probes were 
detected using BM purple (Roche) supplemented with LT (1:100). Depending on the 
embryo stage of the gut and the probe, 1 to 2 days of developing were necessary to 
be concluded. The enzymatic reaction was stopped in PBS, and tissues were stored 
at 4ºC in 4% PFA. 
 
II.4. Embedding and cryosectioning 
Samples for cryosectioning were fixed for 1 hour in 4% PFA, washed with PBS and 
left overnight in solution T1. On the next day, solution T2 was added to samples 
and incubated overnight. Finally, solution T3 was pre-warmed at 37ºC before being 
added to samples. Vials with this solution were left during 1 hour in water bath, being 
agitated once in a while. Once samples were incorporated in blocks with solution T3, 
they were frozen using isopentane cooled (-30/35°C) with dry ice and stored at -
80ºC. Sectioning was performed using a MICROM HM 560 cryostat. Sections were 8 
µm thick, were collected on StarFrost microscope slides (Knittel Glass) and slides 
were left to dry overnight at room temperature for better section adherence. 
 
II.5. Immunohistochemistry 
Slides were washed twice in PBS, 10 minutes each, and permeabilized for 10 
minutes with 0,1% Triton-X100 (Prolabo VWR) in PBS. The blocking was done using 
5% donkey serum (Sigma-Aldrich) in PBS during 30 minutes. Primary antibodies 
were used at the following dilutions: anti-human PROX1 rabbit polyclonal (Reliatech 
GmbH) 1:200, TUJ1 mouse monoclonal (COVANCE) 1:400, α-SMA mouse 
monoclonal (Abcam) 1:300. These dilutions were done in 1% donkey serum in PBS 
and incubation was done overnight at 4ºC. 
Two washes of PBS, 15 minutes each, were performed on the slides to remove the 
primary antibodies. Secondary antibodies Alexa 488-conjugated donkey anti-mouse 
IgG and Alexa 555-conjugated donkey anti-rabbit IgG (Invitrogen, Molecular Probes) 
were diluted 1:400 in a solution of 1% donkey serum in PBS with Hoescht 1:1000 
(Invitrogen) and put on slides during 2 hours. 2 washes of 10 minutes each were 
done and slides were mounted with mounting medium for fluorescent samples 
(Dako). 
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II.6. Image acquisition and treatment 
Whole-mount guts processed for ISH were photographed with a stereomicroscope 
connected to a Nikon-AZ100 digital camera and immunohistochemistry images were 
acquired with a Zeiss AX10 Imager.M1 microscope connected to an AxioCam MRm. 
ImageJ and Adobe Photoshop CS6 softwares were used to analyze and treat all 
images.  
 
II.7. Organ Culture 
II.7.1. Gut collection 
For this experiment 4 groups of samples were created: in ovo E6.5, BAC-treated 
organ culture, organ culture control and in ovo E8.5. 
All eggs were incubated at the same time and taken out from the incubator when 
they reached E6.5. Dissection was performed in fresh PBS and whole gut isolation 
was used for ISH protocol. From this dissection 3 groups were formed: in ovo E6.5 
group, BAC treated organ culture group and organ culture control group. In ovo E6.5 
group was immediately fixed in 4% PFA and dehydrated and eggs that were not 
opened were placed back in the incubator to constitute the last group (in ovo E8.5). 
After 48 hours of incubation organ cultures were washed with PBS and 
fixed/dehydrated. Meanwhile, the in ovo E8.5 group was dissected and samples 
fixed/dehydrated. 
 
II.7.2. Organ culture proceedings 
The 2 culture conditions: BAC and control were washed in DMEM (Dulbecco's 
Modified Eagle Medium; Gibco) supplemented with 1% Penicillin/Streptavidin 
(BioWhittaker, Lonza), 2% Hepes 1M (BioWhittaker, Lonza) and 2% L-Glutamine 
200mM (Sigma-Aldrich) (Medium 1). The BAC group was incubated for 10 minutes in 
a Benzalkonium chloride solution (Sigma-Aldrich) and then washed 3 times with 
medium 1. The Benzalkonium chloride solution was at a concentration of 0.04%. 
Both groups were incubated at 37ºC for 48 hours in a differentiation medium. This 
medium was prepared from medium 1 supplemented with 0,02% BSA (Euromedex) 
and insulin at a concentration of 1 µL/mL. 
 
II.8. Quantitative RT-PCR 
RNA isolation and reverse transcription were done as described in section II.2.1 and 
Annex A1. 1 µg of RNA was used as a template for the reverse transcription reaction. 
For each well the following mix was prepared 2.5 µL of cDNA, 1.5 µL LightCycler480 
SYBR Green I Master water (Roche), 1 µL of mixed primers 0.5 µM (Annex B, Table 
B7) and 5 µL of 2x LightCycler480 SYBR Green I Master (Roche). RT-PCR 
amplification was run with a LightCycler technology (Roche Diagnostics; 95°C for 10 
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seconds, 60°C for 10 seconds, 72°C for 15 seconds) and mRNA quantification was 
determined by LightCycler analysis software (version 3.1). 
 
II.9. Western-Blot 
Proteins from E15 pancreas samples were extracted by adding 200 µL of Laemmli 
4X buffer for 5 minutes at 100ºC. A final disruption of the tissue was done with a 
pipette. 
Samples were loaded into the stacking gel through which they ran at 80V before 
being separated in the running gel for about 80 minutes at 120V in 1X running 
buffer. Proteins were then transferred into a nitrocellulose blotting membrane (GE 
Healthcare) using 1X transfer buffer for 1 hour at 100V. The membrane was 
washed with TBS with 0,1% Tween20 (TBST) and blocked with 5% Skim Milk (BD 
Difco) in TBST for 30 minutes. Three washes were done with TBST before adding 
the primary antibody diluted in 5% Skim Milk in TBST overnight. The anti-human 
PROX1 rabbit polyclonal (Reliatech GmbH) was used at a concentration of 1:1000. 
Four washes of TBST 5 minutes each were done to rinse the antibody. The anti-
rabbit antibody coupled to the horseradish peroxidase (Bethyl laboratories) was 
diluted 1:5000 in 5% Skim Milk in TBST and incubated with the membrane for half an 
hour. Three quick washes with TBST were done and the enhanced 
chemiluminescent substrate from the Western Blotting Luminol Reagent kit (Santa 
Cruz Biotechnology) was put in contact with the membrane for 1 minute. The 
developing was done in darkness by exposing the membrane to a high performance 
chemiluminescence film (GE Healthcare) inside a cassette with BioMax MS 
Intensifying Screen (Kodak BioMax) for 20 seconds. 
 
II.10. Electroporation 
II.10.1. Plasmid injection 
PROX1 and ΔDBD-PROX1 (PROX1 without its DNA-binding domain) plasmids were 
kindly given by Dr. Panagiotis Politis 44 while, U2-DTA (SOX10 enhancer expressing 
diphtheria toxin) plasmid was given by Dr. Christophe Marcelle 45. Plasmid pCIG4 
was also used to express GFP (Annex D3). 
For each experiment, there were always 2 groups: control and injected. Control 
group was only injected with pCIG4, while injected group was injected either by 
PROX1 or ΔDBD- PROX1 or U2-DTA, together with pCIG4. 
PROX1, ΔDBD-PROX1, U2-DTA and pCIG4 were used at a concentration of 2 
µg/µL. pCIG4 when used together with another plasmid was at 1 µg/µL. 
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II.10.2. In ovo 
Embryos were first incubated for about 2.5 days until stage HH16. Injections were 
done in the neural tube, with a microinjector at the level of somite number 25 and 
caudalwards. After microinjection, gold plated electrodes from Cell Porator 
Electroporation System ECM 830 (BTX) were placed on either side of the neural tube 
and the electroporation was performed at 25V (3 pulses of 5ms). Electroporation was 
done bilaterally. Eggs with electroporated embryos were put back in the incubator 
and dissected out at E6.5. Colons were dissected and only the ones showing 
fluorescence were kept for later analysis. Tissue analysis was done either by 
quantitative RT-PCR or immunofluorescence. 
II.10.3. In vitro 
Embryos were dissected at E6 and only colons were kept. Electroporation was 
performed in the NoR and as previously described. Colons were cultured in organ 
culture in the same differentiation medium as used in section II.7.2. After 2 to 4 days, 
colons were taken out from culture, washed with PBS and processed for 
immunofluorescence. 
 
II.11. Sacral neural crest cells ablation 
A window was opened after 2.5 days of incubation at stage HH16. From somite 25 
down to the most posterior part, neural tube was ablated (without touching the 
notochord) using the microinjector needle. Once ablated eggs were placed back in 
the incubator and allowed to reach stage E6.5. Control colons were let incubated 
until E6.5 without neural tube ablation. Colons were then dissected and processed 
for immunohistochemistry assays.  
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Chapter III 
 
 
RESULTS 
 
III.1. Gut lymphatic system development is a late embryonic event 
 
To determine when the LS arises in the gut, whole-mount ISH was performed from 
early (E5) to late (E16) stages of gut development, for genes specific of the different 
endothelial subtypes. LYVE1, PROX1 and PODOPLANIN were used to characterize 
the LS, while CLAUDIN5 was used as a general endothelial cell marker, meaning 
that this gene is expressed in both blood and LS (Figures 8 and 9). 
This comparison among vasculatures revealed a difference in their timing of 
establishment. While the blood vasculature has already developed throughout the 
whole gut at E12 (Figure 8A-C), at that stage no markers of the LS are present within 
the gut mesenchyme (Figures 9B-D). In Figure 9B, two lymphatic vessels are 
observed in the mesentery. Both vasculatures are easily distinguishable in bright field 
(Figure 9A). 
 
Figure 8 - In situ hybridization analysis of vascular network development in the 
intestine and associated mesentery. 
At E12 a well developed blood vasculature is already present in mesentery and intestine (A-
C). 
 
At E13, two large vessels located along the gut express lymphatic markers (Figures 
9F-H). These two vessels most likely are lymphatic collecting vessels (Figure 9E).  
Starting from E14, cells expressing lymphatic vessel genes decrease in number. At 
E14, gene expression still occurs in large vessels (Figures 9J-L), whilst at E15 no 
expression is visible (Figures 9N-P). At E16, formation of smaller vessels can be 
seen in Figures 9Q-S. 
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Figure 9 – In situ hybridization analysis of lymphatic network development in the 
intestine and associated mesentery. 
Bright field visualization of the mesenteric vasculature (A,E,I,M,Q) and ISH in whole-mount 
embryo guts for LYVE1 (B,F,J,N,R), PROX1 (C,G,K,O,S) and PODOPLANIN (D,H,L,P,T) 
from E12 to E16. Starting at E12, both blood (Figures A,E,I,M,Q, black arrows) and lymphatic 
(Figures A,E,I,M,Q, white arrows) vasculatures have developed and are in close proximity. 
LYVE1, PROX1 and PODOPLANIN are strongly expressed in mesenteric lymphatic vessels 
at E13, but their expression decreases after that. The Fabricius bursa (FB, Figure C, 
brackets) and pancreas (P, Figures G and S, black arrowheads) are positive controls for 
PROX1 expression. 
FB 
í	  
í	  
í	  
í	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Although, LYVE1 (Figures 9B and F) and CLAUDIN5 (Figure 8) are both expressed 
in the intestine mesenchyme, only CLAUDIN5 (Figure 8C) depicts the formation of a 
typical vascular network. LYVE1 expression in the mesenchyme is only found at 
these two stages, and given the fact that later during development the probe stains 
lymphatic vessels, this mesenchymal expression is likely due to other functions not 
related to the lymphatic vasculature. 
In addition, PROX1 expression appears in a chicken-specific lymphoid organ, the 
Fabricius bursa (FB, Figure 9C, brackets), and in the pancreas (P, Figure 9G and S, 
arrowheads). PROX1 has been shown to be involved in the development of the 
exocrine pancreas 46.  
 
III.2. Colon lymphatic network forms after the establishment of the 
mesenteric vasculature. 
 
As the technique of whole-mount ISH shows its limits when studying tissues so late 
during development, we decided to look for the presence of protein by 
immunofluorescence. No lymphatic-specific antibodies developed for the chicken 
model are currently commercially available, however we decided to test three 
different antibodies directed against human proteins: PROX1, LYVE1, and 
PODOPLANIN. First, we characterized PROX1 antibody by performing a Western-
Blot and an immunohistochemistry assay into an organ known to express PROX1: 
the exocrine pancreas at E15 (Figure 10). The methodology used to extract nuclear 
proteins does not allow protein quantification in the sample, thus we have loaded 
growing volumes of protein extract in the different wells.  
In all samples we observed one band with an estimated size between 70 and 100 
kDa according to the protein ladder; which corresponds to the expected chicken 
PROX1 protein size of 83 kDa (Figure 10A). In addition, in an immunofluorescence 
assay (Figures 10B'-B'') the PROX1 antibody stains the exocrine pancreas in a 
pattern similar to what has been reported in the literature validating the antibody 
specificity 46. Characterization assays conducted with LYVE1 and PODOPLANIN 
antibodies showed no cross-reaction on chicken samples (data not shown). 
In our immunofluorescence assays, we used the PROX1 antibody in combination 
with the αSMA antibody to visualize the smooth muscle layer surrounding blood 
vessels. Cross-section through these major vessels present in the mesentery 
associated with the gut (Figure 11) show an extensive and intricate lymphatic 
network in close vicinity with blood vessels (Figure 11A'''). As previously observed 
(Figure 9), gut lymphatic vasculature develops at late stages. Techniques of ISH in 
the chick gut have shown their limits after E12 due to organ thickness and 
subsequent difficulty in probe accessibility to the target RNA. Furthermore, due to the 
very few number of cells present in thin capillary structures of the lymphatic system, 
ISH in sections resulted in a very poor staining (data not shown). However, we know 
that a lymphatic system is required for gut functions such as absorption and immunity 
matters 13.  
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Figure 10 - Characterization of PROX1 antibody in the chicken model by Western-Blot 
and immunohistochemistry. 
PROX1 antibody specificity was tested using a protein extract from an E15 pancreas in 
Western-Blot and E15 pancreas sections for immunohistochemistry. Western-Blot analysis 
shows one specific band at the predicted PROX1 protein size of 83 kDa (Figure A). On the 
immunohistochemistry assay, the exocrine pancreas expresses PROX1 (Figures B',B''), 
validating our antibody. http://www.reliatech.de/fileadmin/ds/pa/102-PA32AG.pdf. 
Scale bar: 100µm. 
To overcome these technical limitation of the ISH protocols, we decided to take 
advantage of the PROX1 antibody that we characterized and to look for PROX1 
protein expression patterns by immunohistochemistry assays. Using PROX1 in 
combination with αSMA or TUJ1, we were able to visualize the lymphatic network 
between the muscle layers in order to investigate its potential relationships with the 
blood vascular system and ENS. 
Figure 11 – Blood and lymphatic vessels are closely associated in the mesentery. 
Immunohistochemistry assays on sections were done with antibodies against PROX1 (Figure 
A' and red channel in Figure A''') and αSMA (Figure A'' and green channel in Figure A''') on 
E15 exterior vasculature along the colon. Lymphatic endothelial cells form an extensive 
network (Figure A''', arrows) in proximity to blood vessels (Figure A''', arrowheads). 
Scale bar: 500µm. 
  
í
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We performed immunohistochemistry assays at the same developmental stages 
used in the ISH studies (E12 to E15). As seen in Figures 12B''-H'' and in accordance 
with the literature 47, the αSMA antibody stains three smooth muscle layers, termed 
longitudinal muscle layer (LM), circular muscle layer (CM) and muscularis mucosa 
layer (MM) (Figure 12B''). We can also observe the smooth muscle cell layer 
surrounding blood vessels (Figures 12C'' and D'', arrowheads). Red blood cells are 
unspecifically stained in both green and red channels, showing an orange/yellow 
color (Figures 12F'''-H'''). Regarding PROX1 staining, at E13 no lymphatic network is 
present in the gut though some positive cells are observed outside the colon (Figure 
12B''', arrow). At E14, some LEC have started to enter the colon from the outer 
vasculature into the space between the longitudinal and circular muscle layers, 
staying next to the blood vasculature (Compare Figure 12C'' arrowhead to C''' arrow 
and D'' arrowhead to D''' arrow).  
At E15, the lymphatic network pattern is similar to E14 (Compare Figure 12D''' with 
E'''). PROX1 is expressed in some epithelial cells (Figure 12F''', arrows) but these are 
not involved in lymphatic vessel formation and labeled some neuroendocrine 
epithelial cells. At E18, the lymphatic network has already been developed 
throughout the entire colon; it has entered and passed the circular muscle layer 
(Figure 12G''', arrow) and spread down to the muscularis mucosa muscle layer 
(Figure 12H''', arrow). 
Therefore, in E15-E18 interval of time, the lymphatic network expands from the 
vessels present among the longitudinal and circular muscle layers down to the 
muscularis mucosa muscle layer. 
In a second part we investigated lymphatic system development with relation to the 
ENS establishment (Figure 13). 
Inside the gut, two plexi composing the ENS have been described: the myenteric (or 
Auerbach's) plexus and the submucosa (or Meissner's) plexus 48. In addition, a third 
plexus (pelvic plexus) is found at the posterior end of the gut; it is visible in cross-
section between the colon and Fabricius bursa (Figure 13B'', arrow). The myenteric 
plexus is localized between the longitudinal and circular muscle layer (Figures 13C'' 
and D'', MP) driving gut motility. The submucosa plexus (Figures 13C'' and D'', SP) 
on the submucosa layer provides secretomotor innervation to the mucosa, close to 
the lumen of the gut. These two plexi are connected together by neurons extensions 
(visible in Figure 13C'' as small dots) that innervate the circular muscle layer, 
allowing a proper innervation of all muscle layers. 
At E13, PROX1 is not detected within the gut mesenchyme (Figure 13B''', arrow). 
However, we find it expressed next to it inside the pelvic plexus, a structure labeled 
by the TUJ1 antibody (Figure 13B’’’, arrow). Its pattern of expression and its 
colocalization with TUJ1 are unexpected, as it clearly does not label a lymphatic 
vascular structure, and no PROX1 expression has ever been reported in this region.  
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Figure 12 - Characterization of lymphatic system development in relation to the blood 
vasculature and smooth muscles. 
Immunohistochemistry study performed on sagittal sections of E13 to E18 colon samples (A). 
LS was visualized with PROX1 antibody (B'-H') while blood vessels and smooth muscle 
layers with αSMA (B''-H''). Three different layers of muscle are present from the outer to the 
inner of colon: longitudinal muscle layer (B'',LM), circular muscle layer (B'',CM) and 
muscularis mucosa layer (B'',MM). The LS develops from the outer networks close to blood 
vessels (C'',D'', arrowheads). At E14, it appears to be invading the colon between the outer 
most muscle layer down to the muscularis mucosa muscle layer close to the epithelium 
(C''',D''',G''',H''', arrows). PROX1 expression in some epithelial cells is not related to LS (F''', 
arrows). Autofluorescence of red blood cells is observed in yellow/orange (F'''-H'''). 
Scale bar: 600µm (A); 150µm (B-H). 
 
At E14, PROX1 is found expressed in lymphatic vessels present in the outer most 
layers of the gut and (as previously shown in Figures 12C''' and D'''), this lymphatic 
network extends within the colon into and between the two muscle layers, and along 
the myenteric plexus (Figures 13C''' and D'''). At E15, LEC are present close to the 
myenteric plexus while at E18 they have invaded the circular muscle (Figure 13F''', 
arrow) down to the submucosa, where they stand in close association with two other 
networks: the blood vasculature (Figure 13G''', arrowhead) and the ENS (Figure 
13G''', SP). Interestingly, at E18 PROX1 is found in some epithelial cells not related 
to lymphatic vessels (Figure 13G'''). 
In this first part, we show that lymphangiogenesis in the digestive tract occurs 
relatively late during development (after E14). This was a real concern for the 
research project we wanted to initiate. Indeed, in the chick model the tools and 
techniques we use in the lab request manipulation on very young embryos (around 
E1.5). Although very useful for many stages, these manipulations result in a very 
high death rate on embryos after E9/E10, which is incompatible with the study as we 
originally designed it.  
However, during our investigations we found a very interesting and unexpected place 
of expression for PROX1 (see below). As this process occurs at a developmental 
stage that allows its study in the chicken model, we decided to move to this new 
project. 
 
 
 
 
 
 
í	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Figure 13 - Characterization of lymphatic system development in relation to the enteric 
nervous system. 
Immunohistochemistry study was performed on sagittal sections of E13 to E18 colon samples 
(Figure 13A). LS was visualized with PROX1 antibody (B'-G') and ENS with TUJ1 (B''-G''). 
Two plexi are present from the outer to the inner of colon: myenteric plexus or Auerbach's 
(C'',MP) and submucosa plexus or Meissner's (C'',SP).  LS is in close proximity to the ENS 
(F''',G''',arrows). PROX1 expression in pelvic plexus (B'',B''',arrows) and in some epithelial 
cells is not related to LS (G'''). Autofluorescence of red blood cell is seen in yellow, permitting 
to visualize the vascular system (G''',arrowhead). Scale bar: 150µm. 
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III.3. Sacral neural crest cells express PROX1 in the nerve of Remak 
 
While performing whole-mount ISH for PROX1 at early stages of development, we 
found that it was expressed in a structure unrelated to the LS. This structure, which 
develops alongside the colon and one part of the small intestine, is called the nerve 
of Remak (NoR), and is a part of the ENS that originates from the sacral NCC 22. So 
far, no marker allowing to distinguish between the two types of NCC (vagal and 
sacral) constituting the ENS has been found. In this regard, PROX1 could be the first 
marker specific of sacral-derived ENS cells, and thus we decided to further 
characterize PROX1 presence in the NoR. The NoR develops together with the gut 
from stage E4.5 24 so we initiated our whole-mount ISH time course from E5 to E9. 
To visualize the migration of both waves of NCC that constitute the ENS in the gut 
we used a probe detecting the expression of the SOX10 gene (Figure 14). As we can 
see in Figure 14B, SOX10 is already strongly expressed in the NoR at E5 and this 
expression is maintained in this structure at all the stages we studied (up to E9 - 
Figures 14D, F, H, J) and even later during development (data not shown). In 
contrast, PROX1 expression is more dynamic during development. At E5 and E6 
PROX1 (Figures 14A and C) shows a strong expression in the NoR. However, from 
E7 (Figure 14E, G, I) this expression quickly decreases to be only faintly sustained in 
the pelvic plexus. It is also interesting to observe the wave of the SOX10-positive 
vagal NCC that colonize the gut in an antero-posterior manner. These cells are first 
detected in the cecum at E6 (VNCC, Figure 14D) progressively invading the whole 
cecum at E7 and the colon at E8 (VNCC, Figures 14F and H), and finally reaching 
the most posterior part of the gut by E9 (VNCC, Figure 14J). 
In parallel, to confirm our ISH studies, we performed a quantitative RT-PCR analysis 
to quantify the expression level of both genes during development. These results 
correlate with the observation made by ISH, showing a peak in PROX1 expression in 
the colon at E6, and progressively decreasing at E7, E8 and E9 (Figure 15A). On the 
other hand, SOX10 expression in the colon increases at every developmental stage 
reflecting the progressive colonization by the vagal and sacral NCC (Figure 15B). 
An interesting correlation is observed: PROX1 downregulation takes place when 
sacral derived cells from the NoR start migrating into the colon, around E7-E8. To 
find whether this downregulation is also observed at the protein level, we moved to 
immunohistochemistry assays on colon cross-sections from E6 to E9.5 with PROX1 
and TUJ1 (a neuron specific β-tubulin) antibodies (Figure 16). TUJ1, is used to label 
sacral and vagal NCC.  
At E6-E7 (Figures 16B'',C'',D'') the only population of NCC visible is the one in the 
NoR (sacral NCC). At E7.5 nerve fibers derived from the NoR and expressing TUJ1 
enter the colon external to the circular muscle layer, at the level of the presumptive 
myenteric plexus (MP, Figure 16E''). Vagal NCC are known to migrate in an antero-
posterior wave and from the submucosal to the myenteric plexus. On the contrary, 
sacral NCC migrate from the posterior to the anterior part of the gut (up to the 
umbilical part) colonizing the myenteric plexus first 4,22,23.  
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Figure 14 - PROX1 is expressed in the nerve of Remak at early stages of embryonic 
development. 
At E5, PROX1 is expressed in the NoR (arrowheads NoR), which is seen by SOX10 
expression in an ENS structure (arrowheads NoR). The NoR is only constituted by sacral 
NCC but another type, vagal NCC, is also migrating towards the end of colon (dashed arrows, 
VNCC). After E6, PROX1 starts being downregulated until E9 when it is no longer seen. At 
E9, vagal NCC have colonized the entire colon. Scale bar: 1mm 
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Figure 15 – The peak of PROX1 expression occurs at E6 on the colon. 
Quantitive analysis of PROX1 expression reveals a higher expression of this gene at E6, 
being downregulated afterwards (A). SOX10 expression increases along the time course due 
to sacral and vagal NCC colonization (B). In the graphics, mean values±s.e.m are shown 
relative to GAPDH control. Each measurement was done on three independent cDNA 
preparations. 
 
 
From E8 these two NCC derived populations are present in the colon with two plexus 
visible (Figures 16F'',G'',H'',I'', MP and SP) and at E8.5 we observe fibers connecting 
the myenteric and submucosal plexus (Figure 16G'', arrowhead). 
In agreement with the quantitative RT-PCR results (Figure 15), at E6 there is a peak 
of PROX1 protein in the NoR (Figure 16B'). This peak diminishes, as the organ 
develops. Around E7.5-E8, PROX1 protein decreases in a more noticeable way, 
correlating with sacral NCC entrance into the colon (Compare Figure 16E' with E'' 
and Figure 16F' with F''). PROX1 positive cells that are not positive for TUJ1 are LEC 
(Figures 16B',C',D',E',G',H',I', arrows). 
It is interesting to note that PROX1 protein was never observed in nerve fibers 
projecting from the NoR. At E9 and E9.5 (Figures H' and I') only very few cells still 
have PROX1 protein, which is in correlation with absence of gene expression at this 
stage (Figure 14I); and suggesting that somehow PROX1 is impeding the entrance of 
sacral NCC into the colon.  
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Figure 16 - PROX1 protein decrease is correlated with sacral neural crest cells 
entrance into the colon.  
Immunhistochemistry technique was done on transversal sections of E6-E9.5 colons to 
visualize the NoR (A). PROX1 and TUJ1 antibodies were used to evaluate PROX1 dynamics 
and ENS migration along the time course. Two enteric plexus are present: myenteric (MP) 
and submucosa plexus (SP) and when PROX1 decreases in the nerve, sacral NCC migrate 
to the plexus (F',F''). Additional PROX1 staining, outside the nerve, represents the LEC 
(B',C',D',E',F',G',H',I', arrows). Scale bar: 150µm.  
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In order to determine if cells expressing PROX1 in the NoR are directly derived from 
the sacral NCC, we undertook three different approaches. The first approach was 
based on an in vitro assay, using a drug treatment that chemically ablates the ENS 
and look for its effects on PROX1 expression. After a dissection at E6.5, organs were 
treated with a benzalkonium chloride solution (BAC) and cultured for 48 hours in a 
differentiation medium. ISH on samples dissected at E6.5 show that colons were not 
entirely colonized by vagal NCC (Figure 17A, asterisk) with a migration front located 
just after the cecum, while sacral NCC were present in the NoR (Figure 17A, 
arrowhead). The NoR was also expressing PROX1 at that stage, as shown in Figure 
17B, arrowhead. 
 
Figure 17 - Chemical death of sacral neural crest cells causes absence of PROX1 
expression in the nerve of Remak. 
Organ culture with benzalkonium chloride solution was used to kill ENS of E6.5 guts (A,B) 
and at E8.5 effects were assessed with SOX10 and PROX1 probes (E-H). Culture conditions 
and E8.5 control (C,D) were not in the exact same stage of development but still a difference 
is observable between the two culture conditions. Sacral NCC (arrowheads) deletion leads to 
absence of PROX1 into the NoR (G,H). Vagal NCC front of migration is seen with asterisks. 
Scale bar: 1mm (A,B,E-H), 2mm (C,D). 
 
When dissected at E8.5 SOX10 is expressed within the whole colon and NoR (Figure 
17C), while PROX1 expression is restricted to the pelvic plexus (Figure 17D). 
Comparing E8.5 controls with culture controls (untreated guts cultured for 48 hours) 
a difference of staging is perceptible (compare Figures 17C and D with 17E and F). 
Indeed, in the E8.5 control, vagal NCC have colonized the entire gut, while in the 
culture control, their migration has only reached the middle of the colon. In the E8.5 
control, PROX1 is restricted to the pelvic plexus, whilst in the culture control it is still 
expressed within the NoR. This means that organ culture samples were delayed in 
development by about 12 to 24 hours, showing a developmental stage of E7.5-E8 
(compare Figures 17E and F with 14E-H). Despite these staging issues between 
E8.5 controls and culture conditions, we were still able to observe that organs placed 
* 
* 
* 
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in organ culture followed their development with ENS cells migrating more posterior 
and PROX1 expression starting to decrease as expected. Interestingly, if we now 
compare culture controls with BAC treated guts (Figures 17E and G), we observe a 
clear decrease in SOX10 expression, especially in the NoR and colon (n=5/5), 
indicating a loss of NCC in these areas. Regarding PROX1, its expression was 
completely lost under these conditions (n=4/4) (Figures 17F and H). From this 
experiment, we can conclude that in the organ culture experiment, when we induce 
neuronal cell death with the BAC treatment, the expression of PROX1 is strongly 
inhibited. 
To further confirm our results, we decided to use a second approach consisting of an 
in vivo genetic ablation of sacral NCC (Figure 18). In this experiment, we injected 
and electroporated an U2-DTA plasmid into the caudal neural tube, at the level of 
somite 25 and caudalward at the developmental stage HH16 (about E2.5). This 
construction allows the expression of the diphtheria toxin, in all cells expressing 
SOX10, and thus kills every NCC receiving the construct. As the microinjection was 
done at the sacral level of the neural tube, only sacral NCC and not vagal NCC were 
affected. After microinjection/electroporation embryos were placed back in the 
incubator until they reached E6.5; then colons were dissected and RNA extracted for 
quantitative RT-PCR analysis. As described in Figure 18A, SOX10 expression 
decreases by 14.6% in the colon of electroporated embryos compared to GFP 
electroporated controls, thus validating the technique. In these animals, PROX1 
expression is reduced by 17.2% compared to controls (Figure 18B). In conclusion to 
this experiment we can say that decreasing the number of sacral NCC in the neural 
tube results in a reduction of PROX1 expression in the NoR. Thus these results also 
suggest sacral NCC are the source of PROX1 expressing cells in the NoR. 
Finally, a second in vivo approach was performed again with E2.5 embryos, in which 
the portion of neural tube located next to somite 25 and caudalward was ablated 
(Figure 19A). When successfully done, no sacral NCC are present within the gut 49, 
while in the case of a partial removal, the reduced number of sacral NCC would only 
allow the migration to the most posterior part of the gut and then the formation of a 
shorter NoR. 
Embryos were dissected for analysis at E6.5, which corresponds to a stage where 
both RNA and protein for SOX10 and PROX1 are normally found in the NoR (Figures 
19B and C; 16C-C'''). In our control, colon cross-sections show expression of both 
the neuronal marker TUJ1 and PROX1 in the NoR.  
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Figure 18 - U2-DTA plasmid electroporation into the sacral neural crest cells leads to a 
decrease of PROX1 expression in the nerve of Remak. 
SOX10 diminished 14.6% with an in vivo ablation of sacral NCC (A) and PROX1 had a 
decrease of 17.2%. In the graphics, mean values±s.e.m are shown relative to UBIQUITIN 
control. Each measurement was done on three independent cDNA preparations. 
 
 
This coexpression is found throughout the hindgut, in the anterior part of the cecum 
(Figure 19D''''), the posterior part of the cecum (Figure 19E'''') and in the colon 
(Figure 19F''''). PROX1 positive cells that are not expressing a neuronal marker are 
LEC (Figures 19D'' and F'', arrows). 
When evaluating ablated colons, a divergence depending on the level of the section 
along the antero-posterior axis is noticeable. In the most anterior part of the cecum 
(Figures 19G-G'''') no NoR is seen with TUJ1 staining, and PROX1 is absent as well. 
As we move more posteriorly along the hindgut, the NoR with its TUJ1 and PROX1 
expression are present (Figures 19H-H'''' and I-I''''). This shows that when partially 
ablated, sacral NCC migrate a shorter distance along the hindgut, and that this loss 
of sacral NCC in this region is associated with a loss of PROX1 expression. 
In conclusion to our in vitro and in vivo approaches, we can confirm our hypothesis 
that PROX1 is expressed in the NoR, by the cells derived from the sacral NCC. 
These results make PROX1 the first specific marker of the sacral derived cells of the 
ENS.  
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Figure 19 - Surgical ablation of the end part of the neural tube, causes absence of the 
nerve of Remak formation and a decrease of PROX1 expression. 
Surgical ablation was done as demonstrated in A on E2.5 embryos and effects assessment 
were interpreted at E6.5 embryonic stage with recourse to immunohistochemistry, since at 
E6, PROX1 has been seen to be expressed in the nerve (B,C). 
Different levels along the colon were analyzed and all showed PROX1 in the nerve in control 
samples (D'''',F''''). PROX1 marked by arrows is LEC (D'',F''). In ablated samples and 
depending on section's localization along the antero-posterior axis, the nerve was (G''',H''') or 
was not ablated (I'''). Where the nerve was not present PROX1 was also absent (G'',H''). This 
heterogeneous result in the same colon is due to non-complete ablation of the end part of the 
neural tube. Figure A was adapted from 24. N= notochord; TB= tail bud. 
Scale bar: 1mm (B,C), 150µm (D-I,D'-I'). 
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III.4. Investigation of PROX1 function in sacral neural crest cells/Nerve of 
Remak. 
 
Given the correlation observed between PROX1 downregulation in the NoR and 
sacral NCC entrance into the colon, we hypothesized that PROX1 might be a 
regulator that determines when sacral NCC can migrate out of the nerve. To address 
this question we performed in vivo and in vitro assays including gain and lost-of 
function approaches both based on plasmid microinjection with PROX1- and ΔDBD-
PROX1-pCIG4 constructs and electroporation (Figure 20). 
 
Figure 20 - Experimental design of plasmids electroporation into sacral neural crest 
cells to misregulate PROX1 gene expression. 
In vivo assays were done in E2.5 embryos with plasmids injection into the end part of neural 
tube, around somite 25 and caudalwards (A1-3). Schemes were adapted from 50. Assessment 
of the effects should be done at E6.5 using colons that express GFP into the nerve (A4, 
arrows). In vitro experiments were done with E6 colons that were injected into the NoR (B1 
and B2, arrows) and assessment of the effects should be done at E8 for ΔDBD-PROX1 
plasmid and E10 for PROX1 plasmid. Electroporation was done bilaterally with 25V, 3 pulses 
of 5ms (A3,B3). Scale bar: 1mm. 
 
The in vivo approach was done in embryos at stage HH16 (E2.5) injected into the 
neural tube from somite 25 and caudalwards, and incubated up to stage E6.5 (Figure 
20A). When colons were dissected at E6.5 only the ones expressing GFP in the 
nerve were kept for immunohistochemistry assays (Figure 20, A4). To characterize 
the effect of misregulating PROX1 expression in the NoR, two combinations of 
antibodies were used: anti-GFP with either PROX1 or TUJ1. Anti-GPF antibody is 
used to visualize electroporated cells. Due to experiment troubleshooting and time 
issues, it was not possible for me to analyze the samples with immunohistochemistry 
í	  
í	  
í 	  
í 	  
25 
25 
  Chapter III - Results 
 
	   33 
technique as originally planned. However the expected results are detailed in Table 
1. 
The in vitro approach was performed only in the NoR of E6 colons that were left in 
culture for 2 days, when injected with ΔDBD-PROX1, and 4 days, when injected with 
PROX1 (Figure 20B). The expected results for immunohistochemistry assays are 
detailed in Table 2 and Table 3. 
 
Table 1 - Expected results of immunohistochemistry technique performed in electroporated 
E6.5 embryos. Experimental conditions (PROX1 and ΔDBD-PROX1) should be compared to 
control GFP plasmid (pCIG4) in order to evaluate misregulation effects. Anti-GFP antibody 
should be used to visualize electroporated cells, which are misexpressing PROX1 constructs. 
PROX1 and TUJ1 antibodies should be used to analyze the effects on the NoR in terms of 
Prox1 expression and sacral NCC entrance towards the colon. 
 
  Plasmid injected Antibodies Expected results 
In
 v
itr
o 
E2
.5
 - 
E6
.5
 
C
O
N
TR
O
L 
pCIG4 
 
anti-GFP Mouse 
PROX1 Rabbit 
 
 
Strong presence in the NoR 
 
anti-GFP Rabbit 
TUJ1 Mouse 
 
 
Stains the NoR; 
Sacral NCC have not entered the 
colon 
 
EX
PE
R
IM
EN
TA
L 
  C
O
N
D
IT
IO
N
S 
PROX1 
+ 
pCIG4 
 
anti-GFP Mouse 
PROX1 Rabbit 
 
 
Same as control 
 
 
anti-GFP Rabbit 
TUJ1 Mouse 
 
 
Same as control 
ΔDBD-PROX1 
+ 
pCIG4 
 
anti-GFP Mouse 
PROX1 Rabbit 
 
 
Fewer PROX1 cells in the NoR 
and PROX1 detected in the 
colon 
 
 
anti-GFP Rabbit 
TUJ1 Mouse 
 
Stains the NoR; 
Sacral NCC have already 
entered the colon 
 
 
Regarding these last two approaches that we developed, we were not able to 
generate reproducible convincing data before I left the lab. However these 
experiments should provide us results that are sufficient to confirm (or invalidate) 
PROX1 function in sacral NCC migration out of the NoR. If our hypothesis is 
validated, it will open new insights into the study of diseases related to ENS. PROX1 
being a transcription factor, this discovery could open the door for the identification of 
more new specific markers of sacral derived ENS. Unraveling new signaling 
pathways activated downstream of PROX1 would provide new tools for the study of 
pathologies such as the Hirschsprung disease, but also help differentiate between 
the several types of colonic neuropathies which have been so far improperly 
characterized.  
í	  
í	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Table 2 - Expected results of immunohistochemistry technique performed in electroporated 
E8 colons with pCIG4 and ΔDBD-PROX1. This misregulation is estimated to cause an 
anticipation of sacral NCC entrance into the colon by annulment of PROX1 inhibition effect on 
these cells. Anti-GFP antibody should be used to confirm electroporation localization and 
plasmid insertion. PROX1 and TUJ1 antibodies should be used to analyze the effects on the 
NoR in terms of PROX1 expression and sacral NCC entrance towards the colon. 
 
  Plasmid injected Antibodies Expected results 
In
 v
itr
o 
E6
 - 
E8
 
C
O
N
TR
O
L 
pCIG4 
 
anti-GFP Mouse 
PROX1 Rabbit 
 
 
Very few PROX1 staining in the 
NoR 
 
 
 
anti-GFP Rabbit 
TUJ1 Mouse 
 
 
Stains the NoR; 
NCC are already present in two 
plexi  
 
EX
PE
R
IM
EN
TA
L 
C
O
N
D
IT
IO
N
S 
ΔDBD-PROX1 
+ 
pCIG4 
 
 
anti-GFP Mouse 
PROX1 Rabbit 
 
 
No staining in the NoR (if 
antibody does not recognize this 
altered form of PROX1); 
Eventually some PROX1 cells in 
the colon  
 
 
 
anti-GFP Rabbit 
TUJ1 Mouse 
 
 
Stains the NoR; 
Myenteric plexus develops 
quicker  
 
 
Table 3 - Expected results of immunohistochemistry technique performed in electroporated 
E10 colons with pCIG4 and PROX1. This misregulation is estimated to cause a delay of 
sacral NCC entrance into the colon by maintenance of PROX1 inhibition effect on these cells. 
Anti-GFP antibody should be used to confirm electroporation localization and plasmid 
insertion. PROX1 and TUJ1 antibodies should be used to analyze the effects on the NoR in 
terms of PROX1 expression and sacral NCC entrance towards the colon. 
 
  Plasmid injected Antibodies Expected results 
In
 v
itr
o 
E6
 - 
E1
0 
C
O
N
TR
O
L 
pCIG4 
 
anti-GFP Mouse 
PROX1 Rabbit 
 
 
 
No PROX1 in the NoR  
 
 
anti-GFP Rabbit 
TUJ1 Mouse 
 
 
Stains the NoR; 
Plexi are well developed  
 
EX
PE
R
IM
EN
TA
L 
C
O
N
D
IT
IO
N
S 
PROX1 
+ 
pCIG4 
 
anti-GFP Mouse 
PROX1 Rabbit 
 
 
 
PROX1 is still present in the NoR 
  
 
 
 
 
anti-GFP Rabbit 
TUJ1 Mouse 
 
 
Stains the No; 
More sacral NCC in the NoR, 
and plexi inside colons 
(especially myenteric) are less 
developed  
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Chapter IV 
 
 
DISCUSSION 
 
The initial aim of our study was to investigate the mechanism of lymphatic 
development in the gut. Our results show that lymphatic vasculature within the 
intestine (Figure 9) develops much later than the cardiovascular system (Figure 8). In 
a way, this gap between both vasculature developments was predictable since, it has 
already been reported for the chick that there is an important delay between the 
initiation of angiogenesis from E1 and the first appearance of LECs on the jugular 
lymphatic sacs around E6.5 51,52. We found that lymphangiogenesis occurs quite late 
during the development of the gut (from E14), colonizing the gut from the mesentery 
and developing towards the innermost layers. During our investigations on lymphatic 
development we found that PROX1, a major lymphatic maker, was first expressed 
specifically in the NoR at early stages. This unsuspected expression pattern led us to 
investigate its expression pattern in more detail and we found that PROX1 is a 
specific marker of the sacral NCC present in the NoR, which constitute together with 
the vagal NCC the precursor cells of the ENS. 
 
IV.1. Gut lymphatic network development 
 
Our results show an important delay in the formation of both vasculatures in the gut. 
Indeed no lymphatic structure is observed in the intestine before E14, while 
CLAUDIN5 expression already highlighted the presence of a vascular network in the 
stomach and intestine at E5. We first observe lymphatic vessels in the gut between 
the longitudinal and circular muscle layer, close to the myenteric plexus at stage 
HH40 (E14). Then, in the E15 to E18 interval of time, lymphatic vessels slowly 
migrate towards the submucosa layer. A close proximity between the ENS and blood 
vessels has already been described, with conflicting results on whether the 
development of these two structures influence each other or not 53,54. Here our results 
show at later stages, similar patterns with lymphatic vessels developing close to the 
ENS myenteric and submucosa plexi. Interestingly SEMAPHORIN members, a group 
of molecules implicated in axon guidance, and their receptors the NEUROPILINS, 
are required for both lymphangiogenesis and NCC migration. NEUROPILIN1 is 
expressed by vagal and sacral NCC that sense a SEMAPHORIN 3A gradient, which 
is known to inhibit axon growth of the NoR. When this gradient is retracted from all 
muscle layers into inner submucosa and mucosa layers, axons extend and sacral 
NCC migrate from these extensions into the colon 55. In lymphatic vessels, 
Neuropilin1 has been seen to be involved in valve formation 56. Similarly, Neuropilin2 
is important for NCC migration 57 and as a co-receptor of VEGFR3 plays key-role 
during lymphangiogenesis 58. Such similarities in pathway activation could in part 
explain such a close association during development. 
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What are the origins of gut lymphatic vessels: intrinsic or extrinsic? Recently, 
Winters59 performed an interesting study about the origin and formation of the gut 
mesothelium, a simple squamous epithelium lined over the internal organs, which 
provides a non-adhesive surface for organ movement and is implicated in fluid 
movement and immune surveillance. They show that each mesothelium is derived 
from its own organ. When they performed chick-quail grafts of splanchnic mesoderm 
marked with GFP, labeled cells appeared on mesothelium, muscular layer and 
submucosa at E10. Staining of the mesothelium with αSMA and endothelial markers 
revealed that some GFP splanchnic mesoderm derived cells were positive for 
vascular αSMA and others were neither positive for αSMA nor endothelial markers. 
They could not characterize these last cells but if we remember that lymphatic 
vessels do not have αSMA surrounding them (only the big vessels are surrounded by 
αSMA) and that some lymphangioblasts were proved to be derived from 
mesenchyme and not endothelial cells, these cells could be gut lymphangioblasts 
candidates. While Wilting 51 reported a dual origin for jugular lymphatic system that 
would give rise to the lymphatic vasculature, Schneider 60 saw in one specimen that 
mesenchymal lymphangioblasts in the limb bud contributed to the jugular lymph sac 
without fusing first with jugular vein. These mesenchymal lymphangioblasts originate 
from PROX1-expressing cells in dermomyotomes 51 (Figure 21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 - Scheme of three studies hypothesizing an alternative model for 
lymphangiogenesis from lymphangioblasts. 
 
 
Splanchnic Mesoderm 
gives rise to... 59 
 
Outer epithelium of the gut 
Mesenchyme of the gut 
Mesothelial precursors of the gut 
GFP+  vascular αSMA+ 
GFP+  αSMA-  endothelial - 
PROX1 protein 51  
Jugular section of cardinal vein - endothelial origin 
Scattered cells in dermomyotomes - lymphangioblasts 
Scattered cells in splanchnic mesoderm - lymphangioblasts 
? 
Mesenchymal Lymphangioblasts 
in the limb bud 60 
Fuse with lymph sac without 
 fusing 1st with cardinal vein 
Alternative model for 
lymphangiogenesis 
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If we hypothesize that PROX1 cells in the splanchnic mesoderm give rise to 
lymphangioblasts we could expect that the lymphatic network of the gut arises from 
these cells. They would fuse with the retroperitoneal (mesenteric) lymph sac, then 
extend and form the lymphatic vasculature within the gut and communicate with the 
rest of the body. In addition, we observe at E13 the expression of PROX1 in a few 
colonic smooth muscle cells of the circular and longitudinal muscles (data not 
shown). This expression is not consistent throughout the muscles but only exists in 
the layers next to the myenteric plexus. At E14 we already have some lymphatic 
vessels within these two muscles. These cells in combination with mesenteric lymph 
sac could give rise to the intestine's lymphatic vasculature. 
 
 
IV.2. PROX1 expression and function in the establishment of the sacral 
enteric nervous system. 
 
Our results identified a novel marker of NCC, which allows distinction between vagal 
and sacral populations. The expression of PROX1 is first observed in the NoR at E5, 
and is downregulated only when sacral NCC migrate into the colon/small intestine 
around E7-E8. This correlation is also visible with PROX1 protein, whose decrease is 
more noticeable around E7.5-E8. All of our different in vivo and in vitro approaches 
led us to the conclusion that PROX1 expression in the NoR marks sacral NCC. 
Interestingly, no expression of PROX1 was detected in SOX10-positive vagal NCC 
migrating antero-posteriorly at these stages. Such a specific marker has long been 
looked for. Delalande 24 showed for the first time a difference in expression between 
vagal and sacral NCC. Vagal NCC were seen expressing 4-fold higher RET mRNA 
levels than sacral NCC. From all candidate genes expressed by NCC this was the 
only noticeable difference. This unsuspected expression pattern opens the way for 
new studies, and the identification of PROX1 downstream targets will aid the 
discovery of more sacral NCC-specific markers, providing new tools for the 
characterization of colonic ENS associated pathologies.  
Assuming that our expectations on Tables 1-3 are proved to be true, we would be 
showing that PROX1 has a role in blocking sacral NCC inside the NoR. Given the 
fact that PROX1 protein has a homeodomain, this confers the property to both 
activate and repress transcription of other genes depending on the context.  
Kaltezioti 44 showed both in chick and mouse that PROX1 in the neural tube 
represses NOTCH1. NOTCH1 signaling inhibits neurogenesis, thus PROX1 has a 
role in suppressing NOTCH1 activity, which leads to neural progenitor cell 
differentiation. NOTCH1 and SOX10 together maintain the ENS progenitor pool and 
later on promote gliogenesis. The difference between these two fates may result in 
additional regulatory mechanism acting in different developmental stages 61. Our 
results show that from E5 to E9 SOX10 is expressed in both NoR and migrating 
sacral and vagal NCC, while PROX1 is only expressed between E5 and E8 before 
sacral NCC migration into the colon/small intestine. PROX1 can be a candidate for 
this additional mechanism that regulates dual function of SOX10 and NOTCH1. One 
hypothesis is that before PROX1 expression, SOX10 and NOTCH1 proteins are in 
the NoR maintaining the sacral NCC pool of progenitors. As soon as PROX1 protein 
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is present in the NoR, NOTCH1 starts being downregulated which leads to initial 
neural differentiation. PROX1 downregulation increases NOTCH1 protein levels 
again that together with SOX10 can now induce gliogenesis (Figure 22). However, 
even though NOTCH1 can also help in migration of NCC, when PROX1 is still in the 
NoR, there are already some sacral NCC migration waves into the colon. Another 
pathway also involved in ENS development is HEDGEHOG signaling, which also has 
a role in NCC migration and could inhibit the NOTCH pathway 61,62. 
 
 
 
 
Figure 22 - Model for PROX1 function in sacral enteric nervous system establishment 
in the colon. 
SOX10 and NOTCH1 maintain sacral NCC in an undifferentiated state due to the role of 
NOTCH1 signaling in inhibiting neurogenesis (A). Our results show that PROX1 levels 
become stronger around E6 and we propose that this transcriptor factor has a role in 
suppressing NOTCH1 activity, causing NOTCH1 downregulation. This would permit the 
initiation of neurogenesis (B). Our results also show that PROX1 levels decrease and cease 
around E7.5-E8, which would permit the upregulation of NOTCH1. PROX1 downregulation 
also correlates with sacral NCC entrance (C). At E9, PROX1 is absent in the colon and 
NOTCH1 and SOX10 activity correlates with gliogenesis. Myenteric and submucosa plexi are 
already established (D). 
 
 
 
 
 
 
SOX10 and NOTCH1 
signaling maintain sacral 
NCC in an undifferentiated 
state due to NOTCH1 
inhibition of neurogenesis. 
PROX1 starts to be 
expressed, inhibiting 
NOTCH1. This permits the 
initiation of neurogenesis. 
PROX1 downregulation 
increases NOTCH1 protein 
levels, which with SOX10 
induces gliogenesis. Sacral 
NCC entrance is correlated 
with a decrease in PROX1. 
SOX10 and NOTCH1 
expression is maintained 
and the two plexi develop: 
myenteric and submucosa 
plexus. 
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IV.3. Conclusions 
 
In summary, our data show that PROX1 plays a dual role during gut development. At 
early stages, it appears in the NoR and our hypothesis is that it could have a role in 
regulating either the initial migration of sacral NCC into the gut or their neural 
differentiation. At later stages, PROX1 is not expressed in ENS structure anymore, 
but it is turned on in the lymphatic vasculature, where it is known to play key-roles in 
the regulation of its formation. 
 
IV.4. Future prospects 
 
In order to continue our study on PROX1 function during ENS development, we will 
first need to conclude our misregulation experiments of PROX1 in the NoR and 
validate the assumptions made in Tables 1-3. PROX1 being a transcription factor, 
the future step will be the identification of PROX1 transcriptional target genes. Given 
the specific expression of PROX1 in sacral NCC, this identification could provide us 
the opportunity to identify PROX1-target genes that could participate in conveying 
the specificity of sacral neural crest derived cell into the colon and small intestine. In 
addition, we will focus on PROX1-target genes, which maintain their expression in 
the colon in order to identify invaluable tools to discriminate sacral from vagal NCC in 
pediatric and adult human colon in order to investigate the contribution of sacral 
derived NCC in colonic ENS pathologies. 
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Annex A 
 
 
PROTOCOLS 
 
A1 - cDNA production / RT-PCR (Thermo Scientific kit) 
1. Put the eppendorf containing the total RNA at 70ºC for 5 minutes and then on ice. 
2. Prepare the reverse transcription mix and only add the RNA in the end. 
 
 4 µL 5X cDNA synthesis buffer 
 2 µL dNTP Mix 
 1 µL RNA Primer 
 1 µL Reverse Transcriptase Enhancer 
 1 µL Verso Enzyme Mix 
 1 µg of Template RNA 
 RNase free water (Sigma-Aldrich) 
  
 Final volume = 20 µL 
 
3. Incubate for 30/35 minutes at 42ºC. 
4. Inactivate the enzyme at 95ºC for 2 minutes and stop the reaction on ice. 	  
A2 - Primer design 
NCBI database was used to obtain the mRNA sequences 
(http://www.ncbi.nlm.nih.gov/nuccore). Forward and reverse primers specific to each 
gene were designed (www.ncbi.nlm.nhi.gov/tools/primer-blast) and sequences 
(Annex B, Table B1) were aligned (http://blast.ncbi.nlm.nih.gov/Blast.cgi) to confirm 
the specificity of the final RNA probe. 
 
A3 - PCR reaction and product ligation into plasmid 
For each of our genes of interest, cDNA was amplified by PCR reaction from total 
cDNA, using gene specific forward and reverse primers. PCR conditions are detailed 
in Annex B, Table B2. Correct PCR products size were confirmed on a 2% agarose 
gel (see Annex C for all the recipes) before being inserted into the linearized 
plasmid: pGEM®-T Easy Vector Systems (Promega; Annex D) for LYVE1, 
PODOPLANIN and PROX1 or pBluescript® SK2 (Stratagene; Annex D) for SOX10. 
After bacterial transformation and miniprep amplification, plasmids were sent to 
sequencing to confirm sequences and determine cDNA orientation into the plasmid.
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A4 - Bacteria transformation 
10-15 ng of plasmid (in a maximum volume of 5 µL) was added to 50 µL of DH5α 
competent cells and incubated on ice for 30 minutes. A 42°C heat-shock was done 
for 40 seconds, and the reaction was immediately stopped on ice for 5 minutes. A 
first bacterial amplification step was done in 1 mL of LB medium without antibiotics 
for 1 hour at 37ºC. Then 200 µL of these bacteria were pipetted and plated on a LB 
agar plate with ampicillin, and left overnight at 37ºC. After an overnight culture, 
individual colonies were selected and PCR screened to confirm cDNA insertion 
(Annex B, Table B3). 
 
A5 - Plasmid amplification and extraction  
A single colony was picked from the selective plate and added to 3 mL of LB medium 
with ampicillin (miniprep). It was then placed overnight on a rocker (220 rpm) at 37ºC 
to allow bacterial growth. 1 mL of the miniprep was diluted in 50 mL of LB medium 
with ampicillin (maxiprep) and grown overnight again at 37°C. The next day plasmid 
extraction was carried out using the NucleoBond (Macherey-Nagel) kit, and was 
ressuspended in 100 µL of buffer TE. Plasmids were stored at -20°C. 
 
A6 - Chick embryo powder 43 
1. Collect E7 chicken embryos (eye-less). 
2. Homogenize them in a minimal volume of ice-cold calcium and magnesium-free 
phosphate-buffered saline, pH 7.4 with a homogenizer or a syringe. 
3. Add 4 volumes of ice-cold acetone mix and incubate on ice for 30min. 
4. Centrifuge at 10.000g for 10min and discard the supernatant. 
5. Wash the pellet once with ice-cold acetone and spin again. 
6. Spread the pellet out on Whatman filter paper and grind to a fine powder using a 
pestle. 
7. Let it air dry and store at 4ºC. 	  	  
  
 	   B1 
Annex B 
 
 
TABLES 
 
Table B1 - List of forward and reverse primers used in in situ hybridization probe 
production. 
 
 
Table B2 - PCR program for amplification of the genes of interest. 
 
Temperature Time  
95ºC 60 seconds  
95ºC 60 seconds 
35 cycles 60ºC 60 seconds 
72ºC 60 seconds / kb 
72ºC 10 minutes  	  	  
Table B3 - PCR program to screen cDNA insertion into the bacteria. 
 
Temperature Time  
95ºC 5 minutes  
95ºC 60 seconds 
35 cycles 60ºC 60 seconds 
72ºC 60 seconds / kb 
72ºC 10 minutes  	  	  
Table B4 - List of RNA polymerases and restriction enzymes according to each gene 
of interest. 
 
Gene RNA polymerase 
(Roche) 
Restriction enzyme 
(New England Biolabs) 
CLAUDIN5 T3 Xba1 
LYVE1 SP6 Apa1 
PODOPLANIN T7  SalI 
PROX1 T7 Pst1 
SOX10 T3 EcoRV 
 
RNA Primer Forward Primer Reverse 
LYVE1 AAGGCAATCTCAGACGTGGTC AGTGGGGATACCTCCAAAGACA 
PODOPLANIN AGTTATCATCCGTGCAAACCTCT ACTGCTTTCAGGGCGAGTACC 
PROX1 TGTAAAGTTCAACAGATGCATTACC ATGTTAAGGGTCTCGGGCAA 
SOX10 GCATCGGACAACTCTTCG CCAGTCATAGCCGCTA 
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Table B5 - Time of fixation used according to embryo stage. 
 
Embryo stage Time used with 4% PFA 
<E9 30 minutes 
[E9;E12] 45 minutes 
>E12 1 hour 
 
 
Table B6 - Time used for proteinase K treatment according to embryo stage. 
 
Embryo stage Time used of Proteinase K 
[E6;E7] 15 minutes 
[E8;E9] 20 minutes 
[E10;E16] 30 minutes 	   	  
Table B7 - List of forward and reverse primers used in quantitative RT-PCR 
technique. 
 
Gene Primer Forward Primer Reverse 
GAPDH CGTCCTCTCTGGCAAAG TCACGCTCCTGGAAGATAG 
UBIQUITIN GGGATGCAGATCTTCGTGAAA CTTGCCAGCAAAGATCAACCTT 
PROX1 AATCTCGCCCTACTCGGGAA GGTAATGCATCTGTTGAACTTTACA 
SOX10 GCATCGGACAACTCTTCG CCAGTCATAGCCGCTA 
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RECIPES 
 
§ 2% agarose gel                  
 0.5X TBE 
 Agarose (2 gr per 100mL of TBE) 
 4 µL/100 mL Ethidium Bromide  
 
§ LB agar with ampicillin (1L) 
 10 g Tryptone 
 5 g Yeast extract 
 10 g NaCl 
 ddH20 
 100 µg/mL Ampicillin 
 
§ Hybridization solution 
 50% Formamide 
 5X SSC, pH 4.5 
 1% SDS 
 50 µg/mL Yeast tRNA 
 50 µg/mL Heparin 
 DEPC treated water  
 
§ Solution 1 
 50% Formamide 
 5X SSC, pH 4.5 
 1% SDS 
 DEPC treated water  
 
§ Solution 2 
 50% Formamide 
 2X SSC, pH 4.5 
 DEPC treated water  
 
§ 1X TBST - Levamisole 
 0.14 M NaCl 
 2.7 mM KCl 
 25 mM TrisHCl, pH 7.5 
 O.1% Tween 
 2 mM levamisole 
 DEPC treated water 
 
§ DEPC-treated water 
2 L ddH2O 
 200 µL Diethyl pyrocarbonate 
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§ LT 100X 
 10% Tween 
 0.2 M Levamisole=tetramisole hydrochloryde 
 DEPC treated water  
 
• 0.12 M Phosphate buffer 
 0.12 mM CaCl2 
 0.077 mM Na2HPO4 
 0.023 mM NaH2PO4 
 
§ Solution T1 
 4% Sucrose 
 0.12 M Phosphate buffer 
 DEPC treated water  
 
§ Solution T2 
 15% Sucrose  
 0.12 M Phosphate buffer 
 
§ Solution T3 
 15% Sucrose 
 7.5% Porcine gelatin 
 0.12 M Phosphate buffer 
 
• Laemmli 4X buffer (10mL) 
2 mL 1M Tris-HCl; pH 6.8 
 0.8 g SDS 
 4 mL 10% Glycerol 
 0.4 mL 14.7M β-Mercaptoethanol                 
 1 mL 0.5 M EDTA  
 8 mg Bromophenol Blue                               
 
§ Stacking gel (for 1 gel) 
 0.480 mL Acrylamide 40% 
 0.260 mL Bis-acrylamide 2% 
 0.630 mL Tris, pH=6.8 
 25 µL SDS 20% 
 25 µL APS10% 
 5 µL Temed 
 3.575 mL ddH2O 
 
§ 12% SDS-PAGE running gel (for 1 gel) 
3 mL Acrylamide 40% 
 1.6 mL Bis-acrylamide 2% 
 3.75 mL Tris, pH=8.8 
 50 µL SDS 20% 
 50 µL APS10% 
 5 µL Temed 
 1.55 mL ddH2O
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§ 10X Running buffer 
380 mM Glycine 
 500 mM Tris Base 
 1% SDS 20% 
 
§ 10X Transfer buffer 
500 mM Glycine 
 380 mM Tris base 
 
§ 1X Transfer buffer (1L) 
100 mL 10X transfer buffer 
 200 mL ethanol 
 700 mL ddH20 
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PLASMID MAPS 	  
 D1 - pGEM®-T Easy Vector Systems (Promega) 
 
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  	  
D2 - pBluescript® SK2 (Stratagene) 
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D3 - pCIG4 plasmid (Grapin lab, Denmark) 
 
 
